High dose therapy of breast cancer: current status (Q33706206)

28 July 2017

1 reference

title

High dose therapy of breast cancer: current status (English)

1 reference

28 July 2017

Dawson LK

1

1 reference

28 July 2017

Leonard RC

series ordinal

2

1 reference

28 July 2017

publication date

1 March 1999

1 reference

Critical Reviews in Oncology Hematology

28 July 2017

published in

1 reference

28 July 2017

volume

30

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

35-43

1 reference

ABC of breast diseases. Metastatic breast cancer

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Bone marrow autotransplantation for solid tumors--prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Dose intensity and high dose therapy. Two different concepts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Cryopreserved autologous marrow infusion following high dose cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Tandem autotransplantation for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900038-9

7 January 2021

10.1016/S1040-8428(98)00038-9

Identifiers

DOI

1 reference

28 July 2017

1 reference